# A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

> **NCT03332017** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 217 (actual)

## Conditions studied

- Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT03332017
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-14
- **Primary completion:** 2021-10-08
- **Final completion:** 2024-12-27
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03332017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03332017, "A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03332017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*